(833) 317-6278 
After revising its calculations, CMS removed Gilead’s cancer cell therapies Yescarta and Tecartus, as well as 5 other medicines, from the first set of drugs subject to rebates under a provision of the IRA.
United States (National)
Christopher Newman
Geo Focus
Coverage Attributes:
Beta
Government Announcement:
31
%
Press Release:
30
%
Cites Data:
19
%
Private Sector Announcements:
5
%
Legal Policy Regulation:
5
%
Themes Covered:
Not enough data
Pitching Insights
Christopher Newman’s coverage predominantly focuses on the pharmaceutical industry, particularly around drug development and government announcements. Given this focus, he may be receptive to pitches from experts in pharmaceuticals or healthcare who can provide insights into drug development processes, regulatory changes, or the impact of government decisions on the industry.
As a journalist with significant coverage of government announcements and citations of data, Christopher might value input from professionals familiar with interpreting regulatory changes within the pharmaceutical sector or those able to analyze and contextualize relevant data pertaining to drug development and market trends.
It's worth noting that while his geographic focus is not specified, some articles touch upon global developments like India's moon landing. Therefore, if your pitch relates to international aspects of pharmaceuticals or healthcare policy, it may align well with Christopher’s coverage area.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Journalists With Similar Coverage:
Based on similarity of content.
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
